Blueprint is a Consumer Longevity company founded in 2021 and based in Venice, United States. It has raised $60M in total funding, most recently a Venture in 2025.
| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| Oct 29, 2025 | Venture | $60M | — | — |
No articles ingested yet for Blueprint. Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.
A line of precision-dosed, clinically informed, third-party-tested supplements derived from Bryan Johnson's personal protocol, including the flagship Longevity Mix plus products such as Essential Capsules, Creatine, NAC and antioxidant blends, and collagen peptides. Organized around benefit areas like daily longevity, brain and heart health, energy and stress, and muscle recovery, the supplements are sold direct-to-consumer with published test results. They form the core of Blueprint's commercial offering and its 'measure, then optimize' approach.
Beyond supplements, Blueprint sells functional foods and ingredients such as olive oil, protein powders and bars, nut mixes, and matcha, along with at-home biomarker tests and a Don't Die app that ties tracking and protocol guidance together. The product ecosystem extends Johnson's regimen across nutrition, measurement, and behavior, letting customers adopt pieces of the full protocol. It reflects the brand's positioning as a comprehensive, data-driven longevity lifestyle rather than a single product.
23 patents on file, but none with both an extractable figure and an abstract on Google Patents yet.